Introduction
The current standard of treatment for advanced follicular lymphoma (FL) is immunochemotherapy, which combines the anti-CD20 monoclonal antibody rituximab with a variety of multiagent chemotherapy regimens incorporating anthracyclines (e.g. doxorubicin), anthracenediones (e.g. mitoxantrone), alkylating agents (e.g. cyclophosphamide), or purine analogues (e.g. fludarabine).
1,2 A number of clinical markers have been proposed as tools for refining survival prognostication in FL, most of which rely on the features of the tumor clone. 1, 2 In contrast, a limited set of biomarkers is available to predict treatment outcome in patients with this lymphoma. 3, 4 The activity of drugs employed for the treatment of FL may be affected by the patient's genetic background. The antitumor effect of monoclonal antibodies may be modulated by polymorphisms of the FCg receptors, which are expressed on cells responsible for antibody-dependent cell-mediated cytotoxicity and are devoted to attracting and activating the immune response against antibody-coated tumor cells. 5 While FCg receptor polymorphisms may influence the outcome of rituximab monotherapy in FL, their role in the context of immunochemotherapy is questionable. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] The therapeutic activity of doxorubicin may be modulated by a poly- March 31, 2014 . Manuscript accepted on January 7, 2015 . Correspondence: palumbo.ga@gmail.com Though most follicular lymphoma biomarkers rely on tumor features, the host genetic background may also be relevant for outcome. Here we aimed at verifying the contribution of candidate polymorphisms of FCg receptor, DNA repair and detoxification genes to prognostic stratification of follicular lymphoma treated with immunochemotherapy. The study was based on 428 patients enrolled in the FOLL05 prospective trial that compared three standard-of-care regimens (rituximab-cyclophosphamide-vincristine-prednisone versus rituximabcyclophosphamide-doxorubicin-vincristine-prednisone versus rituximab-fludarabine-mitoxantrone) for the first line therapy of advanced follicular lymphoma. Polymorphisms were genotyped on peripheral blood DNA samples. The primary endpoint was time to treatment failure. Polymorphisms of FCGR2A and FCGR3A, which have been suggested to influence the activity of rituximab as a single agent, did not affect time to treatment failure in the pooled analysis of the three FOLL05 treatment arms that combined rituximab with chemotherapy (P=0.742, P=0.252, respectively). These results were consistent even when the analysis was conducted by intention to treat, indicating that different chemotherapy regimens and loads did not interact differentially with the FCGR2A and FCGR3A genotypes. The genotype of MLH1, which regulates the genotoxic effect of doxorubicin, significantly affected time to treatment failure in patients in the rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone arm (P=0.001; q<0.1), but not in arms in which patients did not receive doxorubicin (i.e., the rituximabcyclophosphamide-vincristine-prednisone and rituximab-fludarabine-mitoxantrone arms). The impact of MLH1 on time to treatment failure was independent after adjusting for the Follicular Lymphoma International Prognostic Index and other potential confounding variables by multivariate analysis. These data indicate that MLH1 genotype is a predictor of failure to benefit from rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone treatment in advanced follicular lymphoma and confirm that FCGR2A and FCGR3A polymorphisms have no impact when follicular lymphoma is treated with rituximab plus chemotherapy (clinicaltrials.gov identifier: NCT00774826).
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We took advantage of the FOLL05 study to clarify the role of FCg receptor polymorphism in advanced FL patients treated with rituximab-based immunochemotherapy and to assess whether MLH1, CYBA and GSTA1 polymorphisms selectively predict the outcome of a specific immunochemotherapy regimen.
Methods

Patients
Peripheral blood samples were prospectively obtained from 428/504 (84.9%) untreated advanced FL patients enrolled in the multicenter, randomized FOLL05 study (Table 1 ; Figure 1 ). 21 The study was designed to assess differences in TTF, which was the primary endpoint of the FOLL05 study (see Online Supplementary Appendix). 21, 22 The REMARK and STREGA guidelines were followed throughout this study. 23, 24 FOLL05 (clinicaltrials.gov identifier: NCT00774826) was conducted in compliance with the Declaration of Helsinki, was approved by the appropriate research ethics committee, required each patient to provide written informed consent and also included centralization of DNA from patients' samples for ancillary studies.
Single nucleotide polymorphism genotyping
Genomic DNA was extracted from peripheral blood samples. Genotyping of the FCGR2A rs1801274, FCGR3A rs396991, 
Statistical analysis
TTF, the primary endpoint of the study, was evaluated according to the intention-to-treat principle and was defined as the time from study entry to last follow-up or to the first of the following events: less than partial remission, a shift to a different therapy for any reason after at least one cycle of treatment, progressive disease, relapse, or death. 21 Molecular studies were blinded to the study endpoints. Analysis of TTF was performed by the KaplanMeier method using the log-rank test to assess differences between genotype groups. 25 The false discovery rate was used to control for multiple statistical testing. 26 Cox regression analysis was used to estimate genotype-specific hazard ratios and 95% confidence intervals, adjusting for potentially confounding covariates. 27 For each SNP genotype, the hazard ratios were generated using common allele homozygotes as the reference group. For SNP with ten or fewer minor allele homozygotes, only the combination of minor allele homozygotes with heterozygotes was analyzed. If this combined frequency was still less than ten, the SNP was removed from the analysis. Proportional hazard regression assumptions were assessed appropriately. Bias corrected c-index, calibration slope and heuristic shrinkage estimator of the Cox model were calculated. 28 Cox model stability was internally validated using bootstrapping procedures. [29] [30] [31] These approaches provided an estimate of the prediction accuracy of the Cox model to protect against overfitting. Categorical variables were compared by the χ 2 test and exact test, when appropriate. All statistical tests were two-sided. Statistical significance was defined as a P value <0.05 and a q value <0.1. The analysis was performed with SPSS v.21.0 and with the R statistical package 3.0.1 (http://www.rproject.org).
Results
FCg receptor polymorphisms have no prognostic impact when advanced follicular lymphoma is treated with chemoimmunotherapy
The clinical features of the 428 patients with advanced FL available for SNP genotyping (84.9% of the whole FOLL05 study cohort; Figure 1 ) did not differ from those of the 76 patients not available for genotyping (Table 1) . These data indicate that the lack of biological material for genotyping was not due to an unintended selection bias. Out of the 428 genotyped cases, the FCGR2A and FCGR3A polymorphisms were assessable in 407 and 406 patients, respectively (Figure 1 ). In the remaining cases, the quality and/or quantity of genomic DNA prevented its amplification and sequencing. The distributions of the FCGR2A and FCGR3A polymorphisms were in HardyWeinberg equilibrium, thus excluding poor genotyping or population biases (Online Supplementary Table S1 ). Patients' characteristics at diagnosis as well as treatment allocation distributed without significant differences across the three genotypes of the FCGR2A and FCGR3A polymorphisms (Online Supplementary Table S2 and S3).
It was planned that all FL patients enrolled in the FOLL05 study, independently of the treatment arm, were to receive eight doses of rituximab combined with chemotherapy. 21 The impact of FCGR2A and FCGR3A genotypes on the primary clinical endpoint of the study (i.e. TTF) was, therefore, initially assessed in the whole study cohort. By pooled analysis of the three treatment arms, TTF was not influenced by the FCGR2A (P=0.742) and FCGR3A (P=0.252) genotypes (Table 2; Figure 2 ). FCGR2A and FCGR3A genotypes did not influence TTF either in clinical subgroups defined by disease bulk or patients' gender, which might affect disease sensitivity to rituximab, or in groups with different prognoses according to the Follicular Lymphoma International Prognostic Index (FLIPI) (Online Supplementary Figures S1, S2 and S3) . The overall response rate also distributed without significant differences across the three genotypes of the FCGR2A (P=0.994) and FCGR3A (P=0.606) polymorphisms. By multivariate analysis, FLIPI and treatment allocation, but not FCGR2A and FCGR3A genotypes, were independent predictors of TTF (Table 2) , thus confirming that the FOLL05 study population included in this genotype-phenotype association analysis is representative of patients with advanced FL.
Patients enrolled in the FOLL05 study were randomized to receive different loads of chemotherapy combined with rituximab, with the lowest load being in the R-CVP arm. 21 In order to verify whether different chemotherapy regimens and loads might interact differentially with FCGR2A and FCGR3A genotypes, the impact of these SNP on TTF was also assessed by treatment arm. However, even when the analysis was conducted by intention-to-treatment arm, TTF did not differ according to FCGR2A and FCGR3A genotypes (Online Supplementary Figure S1 and S2) .
LIke FCg SNP, polymorphisms of GSTA1 and CYBA also had no role in FL outcome prediction (Online Supplementary Figure S4 ).
The genotype of MLH1 is a predictor of R-CHOP treatment failure in advanced follicular lymphoma patients (Figure 1) , and its distribution was in HardyWeinberg equilibrium (Online Supplementary Table S1 ). Among the drugs utilized in the FOLL05 study, MLH1 is known to regulate the genotoxic effects of doxorubicin. 17, 18 According to this biological rationale, the clinical impact of the MLH1 polymorphism was initially assessed in FL patients randomized to the R-CHOP arm. Among FL patients allocated to R-CHOP, characteristics at diagnosis distributed without significant differences across the three genotypes of the MLH1 polymorphism, with the sole exception of a trend towards a more frequent involvement of more than one extranodal site in patients homozygous for the variant allele (Online Supplementary Table S4) . Univariate analysis for TTF, controlled for multiple comparisons by false discovery rate testing, identified the MLH1 polymorphism as a predictor of R-CHOP treatment failure in advanced FL (P=0.011; q<0.1) ( Table 3 ; Figure  3A ). After R-CHOP treatment, FL patients who carried the homozygous GG variant genotype of MLH1 showed a significantly lower 3-year TTF (30.3%) compared to patients who carried the MLH1 AG (3-year TTF: 66.2%) or AA (3-year TTF: 68.8%) genotypes (P=0.010 and P=0.003, respectively, in the pairwise comparisons) ( Figure  3A) . Consistent with the selective involvement of MLH1 in doxorubicin pharmacodynamics, the MLH1 polymorphism did not affect the outcome of FL patients treated with regimens lacking this drug (i.e. R-CVP and R-FM) (Online Supplementary Figure S3) . By multivariate analysis, FL patients who carried the homozygous GG variant genotype of MLH1 displayed a 2.8-fold increase in risk of failing to benefit from R-CHOP (hazard ratio: 2.81; 95% confidence interval: 1.18-6.73; P=0.020), after adjusting for clinically relevant covariates including FLIPI, number of extranodal sites, bone marrow involvement and raised level of beta-2-microglobulin ( Table 3 ). The increased risk of failing to benefit from R-CHOP translated into a significantly shorter overall survival in FL patients harboring the homozygous GG variant genotype of MLH1 ( Figure 3B ).
The genotype of MLH1 predicts reduced benefit from the addition of doxorubicin to treatments for follicular lymphoma
The FOLL05 randomized study demonstrated that R-CHOP significantly improves TTF compared to R-CVP in patients with previously untreated FL, thus documenting a relevant clinical benefit when doxorubicin is added to the R-CVP backbone in this type of lymphoma. 21 Consistent with these clinical data, the addition of doxorubicin to the R-CVP backbone resulted in a significant improvement in the 3-year TTF (19% increase; P=0.002) in FL patients harboring the common allele of MLH1 (AA and AG genotypes) ( Figure 4A ). In contrast, FL patients who carried the homozygous GG variant genotype of MLH1 (~10% of the FOLL05 population) did not gain benefit from doxorubicin ( Figure 4B ).
Discussion
This large prospective substudy of the FOLL05 trial, shows that: (i) FCg receptor polymorphisms do not have a prognostic impact when advanced FL is treated with chemoimmunotherapy; and (ii) the MLH1 genotype is a predictor of failure of R-CHOP treatment in FL.
Although several small studies in FL have shown that FCg receptor polymorphisms may be useful in predicting MHL1 polymorphisms in FL haematologica | 2015; 100 (4) 521 The MLH1 polymorphism is a predictor of R-CHOP treatment failure in advanced FL. Consistent with the selective involvement of MLH1 in doxorubicin pharmacodynamics, [16] [17] [18] the MLH1 genotype did not affect the outcome of FL patients treated with regimens lacking this drug. The selective association between MLH1 genotype and outcome after R-CHOP has been clinically validated in independent retrospective series of lymphoma patients, including two retrospective cohorts of patients with diffuse large B-cell lymphoma and this prospective FL series. 16 Overall, these notions point to MLH1 genotype as a predictor of R-CHOP failure in B-cell lymphoma.
The mechanistic explanation of the phenotype observed in FL patients who carried the homozygous GG variant genotype of MLH1 remains to be clarified. In other disease models, the MLH1 rs1799977 polymorphism associates with reduced MLH1 protein expression in tumor cells. 16, 32, 33 Alternatively, the MLH1 rs1799977 polymorphism might be in linkage disequilibrium with other functionally relevant SNP of the MLH1 gene, 34 suggesting that multiple variants within the MLH1 locus may contribute to the risk of treatment failure in FL.
The association between CYBA and GSTA1 SNP and outcome of R-CHOP treatment was not replicated in the current study cohort. It is likely that moderate sample size, inter-subtype and other genetic heterogeneity, as well as small true effect sizes account for the lack of replication. Alternatively, the lack of replication might be the consequence of the false positive report probability that is known to affect candidate gene association studies, and indicates that, at variance with MLH1 rs1799977, neither CYBA nor GSTA1 SNP represent prognosticators in B-cell lymphomas treated with R-CHOP.
Despite the limitations imposed by the sample size, our data provide a signal of reduced benefit from the addition of doxorubicin to the R-CVP backbone in FL patients harboring the homozygous GG variant genotype of MLH1. Conversely, the MLH1 genotype has no clinical relevance in FL patients treated with R-FM, which, in turns, seems equally effective as R-CHOP in the setting of advanced FL. R-FM might, therefore, represent a suitable initial chemotherapy approach for FL patients carrying the homozygous GG variant genotype of MLH1. Replication of these findings in other cohorts of FL patients will be necessary to assess their generalizability.
The FOLL05 study was designed before the establishment of rituximab maintenance as a standard of care for advanced FL.
2 Furthermore, the FOLL05 study did not include bendamustine-based regimens among its treatment strategies. 2 These facts should prompt investigations aimed at clarifying whether maintenance after initial R-CHOP or bendamustine-based immunochemotherapy might abrogate the prognostic impact of the MLH1 genotype.
